- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055036
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
September 30, 2025 updated by: Joshua Joseph, MD, Ohio State University
Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race/sex group.
Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men.
The team of clinician scientists and community partners co-developed a community-based lifestyle intervention titled Black Impact: a 24-week intervention for Black men with less-than-ideal CVH (<4 LS7 metrics in the ideal range) with 45 minutes of weekly physical activity, 45 minutes of weekly health education, and engagement with a health coach, group fitness trainer, and community health worker.
Single-arm pilot testing of the intervention (n=74) revealed high feasibility, acceptability, and retention and a 0.93 (95% confidence interval: 0.40, 1.46, p<0.001) point increase in LS7 score at 24 weeks.
Secondary outcomes included improvements in psychosocial stress (i.e., perceived stress, depressive symptoms), patient activation, and social needs.
Thus, robustly powered clinical trials are needed to determine the efficacy of Black Impact and to evaluate the underlying interpersonal and molecular pathways by which Black Impact improves psychosocial stress and CVH.
Thus, the investigators propose a randomized, wait-list controlled trial of Black Impact.
This novel, community-based intervention to provide a scalable model to improve CVH and psychosocial stress at the population level and evaluate the biological underpinnings by which the intervention mitigates cardiovascular disease risk.
The proposed study aligns with American Heart Association's commitment to addressing CVH equity through innovative, multi-modal solutions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
340
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Luiza Reopell
- Phone Number: 614-653-8213
- Email: Luiza.Reopell@osumc.edu
Study Contact Backup
- Name: Sean Matambo
- Phone Number: 773-683-9241
- Email: Sean.Matambo@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43202
- Recruiting
- The Ohio State University
-
Contact:
- Luiza Reopell
- Phone Number: 614-653-8213
- Email: Luiza.Reopell@osumc.edu
-
Principal Investigator:
- Joshua Joseph
-
Contact:
- Sean Matambo
- Phone Number: 773-683-9241
- Email: Sean.Matambo@osumc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score < 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio.
Exclusion Criteria:
- healthcare provider-imposed limitations on physical activity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Black Impact Intervention
|
The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes.
The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men.
Each participant will be assigned to a group with >5 participants based on participant proximity to a central community meeting location.
Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity.
Teams meet for 90 minutes per week.
|
|
No Intervention: Black Impact Waitlist Control
Usual Care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiovascular Health
Time Frame: 24 weeks
|
The primary outcome for the randomized controlled trial is change in cardiovascular health at 24-week follow-up, which will be calculated using between-subject differences rather than within-subject differences, using a linear mixed-effects to evaluate changes from baseline in Life's Essential 8 score (range 0-100, higher scores are better).
Study wave will be a covariate in the models.
The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks).
These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator.
Residual plots will examine model assumptions and model fit, with transformation of the outcomes (e.g.
log, square-root, Box-Cox) used as needed to satisfy modelling assumptions (e.g.
normality, constant variance) and achieve appropriate model fit.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Perceived Stress
Time Frame: 24 weeks
|
Change in psychosocial stress (perceived stress) will be examined using changes in the perceived stress scale via linear mixed models with subject level random effects to account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Blood Pressure
Time Frame: 24 weeks
|
Change in Life's Essential 8 Blood Pressure (range 0-100, higher is better) will be measured via an automated sphygmomanometer and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Blood Lipids
Time Frame: 24 weeks
|
Change in Life's Essential 8 Blood Lipids via Non-HDL Cholesterol (range 0-100, higher is better) will be measured via a blood sample and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Blood Glucose
Time Frame: 24 weeks
|
Change in Life's Essential 8 Blood Glucose via hemoglobin A1c (range 0-100, higher is better) will be measured via a blood sample and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Body Mass Index
Time Frame: 24 weeks
|
Change in Life's Essential 8 Body Mass Index via body mass index measurement from height (meters) and weight (kilograms), calculated as kilograms per meter squared (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Diet (subjective)
Time Frame: 24 weeks
|
Change in Life's Essential 8 Diet (subjective) measured via the 16-item Mediterranean Eating Pattern for Americans (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Diet (objective)
Time Frame: 24 weeks
|
Change in Life's Essential 8 Diet (objective) measured via dermal carotenoids using the Veggiemeter (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Physical Activity (subjective)
Time Frame: 24 weeks
|
Change in Life's Essential 8 Physical activity (subjective) measured via self-reported minutes of moderate or vigorous PA per week (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Physical Activity (objective)
Time Frame: 24 weeks
|
Change in Life's Essential 8 Physical activity (objective) measured via 1 week of accelerometry using an actigraph watch (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Nicotine Exposure
Time Frame: 24 weeks
|
Change in Life's Essential 8 nicotine exposure measured via self-reported use of cigarettes or inhaled nicotine delivery system (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Life's Essential 8 Sleep Health
Time Frame: 24 weeks
|
Change in Life's Essential 8 sleep health measured via self-reported average hours of sleep per night (range 0-100, higher is better) and examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in Central Aortic Pressure
Time Frame: 24 weeks
|
Change in central aortic pressure (mmHg) measured via the Sphygmocor XCEL device will be examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in carotid-femoral pulse wave velocity
Time Frame: 24 weeks
|
Change in carotid-femoral pulse wave velocity (meters/second) measured via the Sphygmocor XCEL device will be examined using linear mixed models with subject level random effects will account for longitudinal measures on each subject, with treatment by time interactions testing differences in changes over time across study arms.
Model fitting strategy will check model specification and fit by examining concordance with distributional assumptions.
|
24 weeks
|
|
Change in patient activation
Time Frame: 24 weeks
|
Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data on patient activation measured via the Patient Activation Measure at 12 and 24 weeks using the analytic framework described in the primary outcome.
Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights.
The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis.
The investigators will use Nvivo to facilitate coding and analysis.
Mechanistic understanding of observed cardiovascular health will ultimately be enhanced via narrative based integration of qualitative and quantitative data.
|
24 weeks
|
|
Change in Social Needs
Time Frame: 24 weeks
|
Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social needs.
The quantitative analysis will use the data from the Centers for Medicare and Medicaid Services Accountable Health Communities Health-Related Social Needs Screening Tool at 12 and 24 weeks using the analytic framework described in the primary outcome.
Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights.
The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis.
The investigators will use Nvivo to facilitate coding and analysis.
|
24 weeks
|
|
Change in Social Functioning
Time Frame: 24 weeks
|
Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social functioning.
The quantitative analysis will use the data from the Patient-Reported Outcomes Measurement Information System Social Function scales at 12 and 24 weeks using the analytic framework described in the primary outcome.
Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights.
The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis.
The investigators will use Nvivo to facilitate coding and analysis.
|
24 weeks
|
|
Change in Social Relationships
Time Frame: 24 weeks
|
Convergent parallel mixed methods will be used to integrate the quantitative and qualitative data to capture the effect of the intervention on social relationships.
The quantitative analysis will use the data from the Patient-Reported Outcomes Measurement Information System Social Relationships scales at 12 and 24 weeks using the analytic framework described in the primary outcome.
Qualitative analysis will involve in-depth immersion in the transcripts and audio and the iterative creation and synthesis of analytical memos and codes to organize data toward thematic insights.
The investigators will use a deductive-dominant approach wherein a subset of central codes are determined a priori to focus the analysis, with inductive emergence of additional codes during analysis.
The investigators will use Nvivo to facilitate coding and analysis.
|
24 weeks
|
|
Change in Hair Cortisol
Time Frame: 24 weeks
|
Evaluation of hair cortisol measured via collection of hair from the vertex of the scalp at baseline, 12, and 24 weeks.
Changes in hair cortisol over time.
which will be calculated using between-subject differences rather than within-subject differences, using a linear mixed-effects to evaluate changes from baseline in hair cortisol.
Study wave will be a covariate in the models.
The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks).
These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator.
Residual plots will examine model assumptions and model fit, with transformation of the outcomes (e.g.
log, square-root, Box-Cox) used as needed to satisfy modelling assumptions (e.g.
normality, constant variance) and achieve appropriate model fit.
|
24 weeks
|
|
Change in Conserved Transcriptional Response to Adversity
Time Frame: 24 weeks
|
Evaluation of change in conserved transcriptional response to adversity (CTRA) will be measured via collection of blood and measuring leukocyte gene expression to determine the CTRA at baseline, 12 and 24 weeks.
For the CTRA score, background subtraction and normalization of raw data, and operationalize inflammatory and antiviral gene activity will be performed.
CTRA change will be calculated using between-subject differences using a linear mixed-effects to evaluate changes from baseline.
Study wave will be a covariate in the models.
The model will contain data from baseline (0 weeks), during-intervention (12 weeks), and post-intervention (24-weeks).
These models will assess differences between waitlist control and intervention participants using an interaction between time and treatment indicator.
Residual plots will examine model assumptions and model fit, with transformation of the outcomes used as needed to satisfy modelling assumptions and achieve appropriate model fit.
|
24 weeks
|
|
Change in Gut Microbiome Health
Time Frame: 24 weeks
|
Gut microbiome health will be assessed at baseline, 12 and 24 weeks.
Participants will collect stool into a collection tube.
Full-length 16S Sequencing using PacBio SMRT-Cell platform will be used for microbiome community structure and alpha diversity analysis.
The Shoreline Biome Complete StrainID Kit will be used for full length 16S library prep and sequencing will be performed at the Nationwide Children's Hospital Institute for Genomic Medicine Research.
Sequences will be classified into Amplicon Sequence Variants (ASVs) using DADA2 and all statistical analysis will be performed using QIIME2, Songbird, and Qurro.
Metagenomic sequencing will be performed by the OSUCCC Genomics Shared Resource using the Illumina NovaSeq SP Flow Cell from libraries produced with the KAPA Library System.
Sequence filtering and scaffold assembly will be performed as (Co-I Proj 2 Gur) published, using MEGAHIT specifically.
Differentially abundant genes will be identified with DESeq2, an R package.
|
24 weeks
|
|
Identify the organizational context and resources necessary to align, coordinate, and sustain academic-community-government partnerships focused on advancing cardiovascular health equity.
Time Frame: 156 weeks
|
To determine the context and resources necessary to align, coordinate and sustain partnerships to advance health equity we will perform interviews with partners in the Black Impact intervention, take notes on partner meetings and review organizational documents.
Through qualitative thematic analysis and structured content analysis of notes taken during on-site contextual inquiry and excerpts from key organizational documents we will develop themes.
The themes, within and across data sources, will be summarized visually and narratively for presentation to organizational stakeholders during a series of co-creation sessions during which stakeholders will leverage insights from qualitative analyses to discuss and detail actions that can lead to greater alignment and coordination for current and future delivery of Black Impact and similar programs aimed at advancing cardiovascular health equity through academic-community-government partnerships.
|
156 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Joshua Joseph, MD, Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Joseph JJ, Gray DM 2nd, Williams A, Zhao S, McKoy A, Odei JB, Brock G, Lavender D, Walker DM, Nawaz S, Baker C, Hoseus J, Price T, Gregory J, Nolan TS. Addressing non-medical health-related social needs through a community-based lifestyle intervention during the COVID-19 pandemic: The Black Impact program. PLoS One. 2023 Mar 9;18(3):e0282103. doi: 10.1371/journal.pone.0282103. eCollection 2023.
- Addison S, Yang Y, Metlock F, King M, McKoy A, Williams A, Gregory J, Gray DM 2nd, Joseph JJ, Nolan TS. The Role of Social Support in Cardiovascular Clinical Trial Participation among Black Men: Black Impact. Int J Environ Res Public Health. 2022 Sep 23;19(19):12041. doi: 10.3390/ijerph191912041.
- Joseph JJ, Nolan TS, Williams A, McKoy A, Zhao S, Aboagye-Mensah E, Kluwe B, Odei JB, Brock G, Lavender D, Gregory J, Gray DM 2nd. Improving cardiovascular health in black men through a 24-week community-based team lifestyle change intervention: The black impact pilot study. Am J Prev Cardiol. 2022 Jan 13;9:100315. doi: 10.1016/j.ajpc.2022.100315. eCollection 2022 Mar.
- Nolan TS, Williams A, Gillespie SL, Gur T, Walker D, Garner JA, Galley J, Reopell L, Wilson A, Lartey K, Ojembe N, Hubbard A, Ballas J, Appana B, Aboagye-Mensah E, Smith S BS, Griffin M BS, Zhao S, Brock GN, Baker C, Hoseus J, Briggs D, Gregory J, Roberts MW, Porter M, Joseph JJ. Design of Black Impact: A Randomized Controlled Trial Evaluating the Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention. J Am Heart Assoc. 2025 Sep 25:e039380. doi: 10.1161/JAHA.124.039380. Online ahead of print.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 24, 2023
Primary Completion (Estimated)
March 31, 2026
Study Completion (Estimated)
March 31, 2027
Study Registration Dates
First Submitted
September 13, 2023
First Submitted That Met QC Criteria
September 19, 2023
First Posted (Actual)
September 26, 2023
Study Record Updates
Last Update Posted (Estimated)
October 6, 2025
Last Update Submitted That Met QC Criteria
September 30, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Insulin Resistance
- Hyperinsulinism
- Overweight
- Dyslipidemias
- Lipid Metabolism Disorders
- Pathological Conditions, Signs and Symptoms
- Behavior
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Hypertension
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Metabolic Syndrome
- Prediabetic State
- Hyperlipidemias
- Sedentary Behavior
- Smoking
Other Study ID Numbers
- 2023H0180
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on Black Impact Intervention
-
Uppsala University HospitalUppsala University; The Kamprad Family Foundation for Entrepreneurship, Research... and other collaboratorsCompletedContinuity of Patient CareSweden
-
M.D. Anderson Cancer CenterRecruiting
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknown
-
George Mason UniversityNational Institute on Drug Abuse (NIDA)UnknownSubstance Abuse | HIV Risk | Shame | Crime | Criminogenic ThinkingUnited States
-
Copenhagen University Hospital at HerlevRecruitingProstate CancerDenmark
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Rhode Island HospitalUniversity of Wisconsin, MadisonCompletedCyberbullyingUnited States
-
New York State Psychiatric InstituteCompletedDepression | Mental Health Disorder | Adolescent Behavior | Stigma, SocialUnited States
-
University of NebraskaKansas State University; Iowa State UniversityCompleted
-
Children's Hospital Medical Center, CincinnatiUniversity of Oklahoma; Oklahoma State University; Dayton Children's HospitalCompletedLymphoma | Leukemia | Solid Tumor | Brain TumorUnited States